N/A
Completed N=140
Noradrenergic Activity and Attention
Source: ClinicalTrials.gov NCT05120713 ↗Enrolled (actual)
140
Serious AEs
0.0%
Results posted
Sep 2024
Primary outcomePrimary: Initial Eye-movements Toward Target and Distractor Shapes Measured by an Eye-tracker — 3.8; 4.4; 3.6; 4.5 percentage of first saccades
Summary
Older adults demonstrate increased distractibility by task-irrelevant information which contributes to general cognitive impairment. However, it is yet unclear how changes in noradrenergic activity during aging influences attentional control. In the current study, tonic noradrenergic activity will be increased or decreased to investigate its behavioral and neural effects on attentional control.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Initial Eye-movements Toward Target and Distractor Shapes Measured by an Eye-tracker |
3.8; 4.4; 3.6; 4.5 | — |
Eligibility Criteria
Inclusion Criteria
- Fluent in English
- Aged between 18-35 or 50-80
- Have normal or corrected-to-normal vision and hearing, and normal color vision
- Have a mobile phone and email address
Exclusion Criteria
- Non-English speakers
- Currently practicing any relaxation, meditation, or breathing technique for more than an hour per week
- Have participated in studies measuring attentional capture in the past year
- Experiencing symptoms of dementia
Data sourced from ClinicalTrials.gov (NCT05120713). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.